Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Long-Acting numbing shot could ease pain after major abdominal surgery

NCT ID NCT07667439

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a long-acting numbing drug (liposomal bupivacaine) can reduce pain for up to 72 hours after open upper abdominal surgery. 148 adults having liver, stomach, or pancreatic surgery will get either the long-acting drug plus standard numbing, or standard numbing alone. The goal is to see if the long-acting version provides better and safer pain relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal bupivacaine plus bupivacaine hydrochloride
What this could lead to
If it works, this could provide a longer-lasting, safer way to manage pain after major abdominal surgery, reducing the need for strong painkillers.
What could go wrong
This is a small, early-stage trial (148 people) at one hospital. The benefit may be small or not apply to all surgeries, and there is a risk of side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery. 2. Patients receiving general anesthesia with tracheal intubation. 3. Aged from 18 to 80 years old. 4. Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ. 5. Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form. Exclusion Criteria: 1. Pregnant or lactating women. 2. Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system. 3. Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time \> 38 s, or platelet count \< 80×10⁹/L. 4. Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency. 5. Skin infection at the puncture site for erector spinae plane block (ESPB). 6. Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate. 7. Current obstructive or restrictive pulmonary disease. 8. Patients with BMI greater than 30 kg/m². 9. Drug abuse, long-term regular use of analgesics, or allergy to the study drugs. 10. Patients who refuse to provide informed consent. 11. Those enrolled in other randomized controlled trials simultaneously or with other conditions unsuitable for participation in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erector spinae plane block are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • the Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.